By InvitationNot Applicable

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

United States, Hong Kong, Moldova45 participantsStarted 2025-12-25

Plain-language summary

Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.

Age range19 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study
✓. Participant, or their legally authorized representative, has provided signed informed consent.

Safety to assess frequency, severity, and outcome of delayed adverse events

Timeframe: 15 years

NCT IDNCT07254208

SponsorPrecision BioSciences, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2040-01